Beyond A-Beta: New Approaches To Alzheimer’s
Executive Summary
The Alzheimer’s Association International Conference is under way in Vancouver through July 19, but some of the most anticipated news regarding drug development for the disease is likely to take place later this year. There’s plenty of hope, but not much optimism that pivotal trials for bapneuzumab and solanezumab will succeed. Regardless of the outcome, the results will have an impact on which approaches to Alzheimer’s come next—and how they get funded.
You may also be interested in...
Alzheimer’s R&D In Brief: Roche’s Crenezumab Misses Endpoints, Novartis Plans Large New Genetic Study
In data presented at the Alzheimer's Association International Conference in Copenhagen, held July 12-17, Roche’s anti-amyloid beta antibody misses endpoints in two Phase II studies, but there were some promising signs of efficacy.
Investors Lend Satori $15 Million, Hoping It Converts To An Alzheimer's Treatment
The venture-backed Cambridge, Mass. firm says it can get its small-molecule gamma-secretase modulator into the clinic next year.
New Cambridge-Elan Centre To Focus On Alzheimer's With $10 Million From Elan
Ireland's Elan Corp. launches a $10 million center for neuroscience R&D with University of Cambridge academics.